Cover Image
市場調查報告書

Pharma Mar, S.A.的產品平台分析

Pharma Mar, S.A. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192773
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Pharma Mar, S.A.的產品平台分析 Pharma Mar, S.A. - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 44 Pages
簡介

Pharma Mar, S.A. ha是探索、開發及銷售由海洋產物提煉之抗癌劑之生物醫藥品企業,致力於開發罕見疾病的治療藥。

本報告提供Pharma Mar, S.A.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Pharma Mar, S.A.的基本資料

  • Pharma Mar, S.A.概要
  • 主要資訊
  • 企業資料

Pharma Mar, S.A.:R&D概要

  • 主要的治療範圍

Pharma Mar, S.A.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Pharma Mar, S.A.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Pharma Mar, S.A.:藥物簡介

  • plitidepsin
  • trabectedin
  • lurbinectedin
  • PM-00104
  • PM-060184

Pharma Mar, S.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Pharma Mar, S.A.:最近的開發平台趨勢

Pharma Mar, S.A.:暫停中的計劃

Pharma Mar, S.A.:開發中止的開發中產品

Pharma Mar, S.A.:企業理念

Pharma Mar, S.A.:總公司和子公司的所在地

  • 總公司
  • 其他分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07318CDB

Summary

Global Markets Direct's, 'Pharma Mar, S.A. - Product Pipeline Review - 2015', provides an overview of the Pharma Mar, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharma Mar, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pharma Mar, S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharma Mar, S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharma Mar, S.A.'s pipeline products

Reasons to buy

  • Evaluate Pharma Mar, S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharma Mar, S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharma Mar, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharma Mar, S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharma Mar, S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharma Mar, S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pharma Mar, S.A. Snapshot
    • Pharma Mar, S.A. Overview
    • Key Information
    • Key Facts
  • Pharma Mar, S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Pharma Mar, S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Pharma Mar, S.A. - Pipeline Products Glance
    • Pharma Mar, S.A. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Pharma Mar, S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Pharma Mar, S.A. - Drug Profiles
    • trabectedin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lurbinectedin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plitidepsin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PM-060184
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pharma Mar, S.A. - Pipeline Analysis
    • Pharma Mar, S.A. - Pipeline Products by Target
    • Pharma Mar, S.A. - Pipeline Products by Route of Administration
    • Pharma Mar, S.A. - Pipeline Products by Molecule Type
    • Pharma Mar, S.A. - Pipeline Products by Mechanism of Action
  • Pharma Mar, S.A. - Recent Pipeline Updates
  • Pharma Mar, S.A. - Dormant Projects
  • Pharma Mar, S.A. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ES-285
      • elisidepsin
  • Pharma Mar, S.A. - Company Statement
  • Pharma Mar, S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pharma Mar, S.A., Key Information
  • Pharma Mar, S.A., Key Facts
  • Pharma Mar, S.A. - Pipeline by Indication, 2015
  • Pharma Mar, S.A. - Pipeline by Stage of Development, 2015
  • Pharma Mar, S.A. - Monotherapy Products in Pipeline, 2015
  • Pharma Mar, S.A. - Pre-Registration, 2015
  • Pharma Mar, S.A. - Phase III, 2015
  • Pharma Mar, S.A. - Phase II, 2015
  • Pharma Mar, S.A. - Phase I, 2015
  • Pharma Mar, S.A. - Pipeline by Target, 2015
  • Pharma Mar, S.A. - Pipeline by Route of Administration, 2015
  • Pharma Mar, S.A. - Pipeline by Molecule Type, 2015
  • Pharma Mar, S.A. - Pipeline Products by Mechanism of Action, 2015
  • Pharma Mar, S.A. - Recent Pipeline Updates, 2015
  • Pharma Mar, S.A. - Dormant Developmental Projects,2015
  • Pharma Mar, S.A. - Discontinued Pipeline Products, 2015
  • Pharma Mar, S.A., Subsidiaries

List of Figures

  • Pharma Mar, S.A. - Pipeline by Top 10 Indication, 2015
  • Pharma Mar, S.A. - Pipeline by Stage of Development, 2015
  • Pharma Mar, S.A. - Monotherapy Products in Pipeline, 2015
  • Pharma Mar, S.A. - Pipeline by Top 10 Target, 2015
  • Pharma Mar, S.A. - Pipeline by Top 10 Route of Administration, 2015
  • Pharma Mar, S.A. - Pipeline by Top 10 Molecule Type, 2015
  • Pharma Mar, S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top